A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
Study Details
Study Description
Brief Summary
A pilot study using remote monitoring technology developed by Locus Health in cancer patients undergoing chemotherapy treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Modern-day wearable devices, such as Apple Watches or Fitbits, are widely available, non-invasive, and can provide continuous vital sign monitoring for the early detection of potential health complications. Early detection of things such as fever or increased heart rate can alert patients to seek medical attention sooner and therefore have the potential to improve patient outcomes and decrease healthcare costs.
To further investigate the feasibility of using remote patient monitoring ( RPM)to prospectively monitor patients undergoing outpatient chemotherapy for chemotherapy related toxicities, defined as follows: (1) patients answer queries through the Locus Health iPhone app at least 70% of the time; (2) patients report that the Locus Health iPhone app and the Apple Watch were 'easy to use,' defined as an average score of 7 or higher on the first two questions of the post-intervention questionnaire, and (3) fewer than 10% of patients withdraw from the study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| 3 Cohorts Cohort 1: Daily from day 2 through the end of treatment cycle (n=34) Cohort 2: Daily days 2-9 then every third day through end of cycle (n=33) Cohort 3: Daily days 2-9 for all symptoms, every third day thereafter regarding 'pain' only through end of cycle (n=33) |
Device: Locus Health iPhone App
In this pilot study patients are enrolled into three (3) different groups which will vary by the frequency of the queries being sent to the patients during their chemotherapy cycle. The patients will be separated into three groups of 33-34 patients each. Each group will have a different frequency of symptom questions sent to them via the Locus Health iPhone App to determine patient fatigue and the compliance impact of different query cadences. Patients will be assigned to these 3 groups sequentially since the platform could not assign patients to these three cohorts in a random manner.
|
Outcome Measures
Primary Outcome Measures
- Participants' use of Locus Heath iPhone App and the Apple Watch to monitor chemotherapy related toxicities [120 days or until the chemotherapy regimen has stopped, whichever is sooner]
The remote monitoring technology (the Locus Heath iPhone App and the Apple Watch) is being used to prospectively monitor patients undergoing outpatient chemotherapy for chemotherapy related toxicities, defined as at least 80% of patients wear the watch at least 70% of the time during waking hours.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Planned to be treated with a new cytotoxic chemotherapy or chemoimmunotherapy regimen for a solid tumor or malignant hematology condition for at least 4 months
-
ECOG performance status of 0-2
-
Age of 18 or older patient with any solid tumor or hematologic malignancy
-
English or Spanish speaker
-
Own an Apple iPhone
-
Capacity and willingness to provide informed consent
Exclusion Criteria:
-
Patients undergoing concurrent radiation since they will be seen on a daily basis by clinic care teams and are not likely to benefit from active remote patient monitoring
-
Patients unwilling or unable to comply with the protocol, including wearing the Apple Watch (including recharging daily) and answering queries on the Locus Health iPhone application per the protocol and study group cadence
-
Any condition for which in the Investigator's opinion would limit compliance with study requirements
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Inova Schar Cancer Institute | Fairfax | Virginia | United States | 22031 |
Sponsors and Collaborators
- Inova Health Care Services
Investigators
- Principal Investigator: John Deeken, MD, Inova Schar Cancer Institute
Study Documents (Full-Text)
None provided.More Information
Publications
- Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006 May 15;106(10):2258-66. doi: 10.1002/cncr.21847.
- Zimmer AJ, Freifeld AG. Optimal Management of Neutropenic Fever in Patients With Cancer. J Oncol Pract. 2019 Jan;15(1):19-24. doi: 10.1200/JOP.18.00269.
- U23-08-5132